Versartis Inc (VSAR) SVP Sells $26,122.60 in Stock

Versartis Inc (NASDAQ:VSAR) SVP Paul Westberg sold 1,316 shares of Versartis stock in a transaction dated Wednesday, April 19th. The shares were sold at an average price of $19.85, for a total transaction of $26,122.60. Following the sale, the senior vice president now directly owns 68,228 shares in the company, valued at approximately $1,354,325.80. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Paul Westberg also recently made the following trade(s):

  • On Monday, February 27th, Paul Westberg sold 12,500 shares of Versartis stock. The shares were sold at an average price of $22.50, for a total transaction of $281,250.00.
  • On Thursday, February 23rd, Paul Westberg sold 25,000 shares of Versartis stock. The shares were sold at an average price of $18.75, for a total transaction of $468,750.00.
  • On Monday, January 30th, Paul Westberg sold 1,916 shares of Versartis stock. The stock was sold at an average price of $13.85, for a total transaction of $26,536.60.

Versartis Inc (NASDAQ:VSAR) opened at 15.95 on Friday. The stock has a 50 day moving average of $19.03 and a 200 day moving average of $16.51. The company’s market cap is $561.57 million. Versartis Inc has a 52 week low of $8.10 and a 52 week high of $24.00.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by $0.14. On average, analysts expect that Versartis Inc will post ($2.84) earnings per share for the current year.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

ILLEGAL ACTIVITY WARNING: This news story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2017/05/20/versartis-inc-vsar-svp-sells-26122-60-in-stock-updated-updated-updated.html.

Several research firms recently commented on VSAR. Piper Jaffray Companies boosted their price objective on shares of Versartis from $22.00 to $26.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 4th. Barclays PLC began coverage on shares of Versartis in a research note on Thursday, March 9th. They set an “overweight” rating and a $28.00 price objective on the stock. Canaccord Genuity reissued a “buy” rating and set a $28.00 price objective on shares of Versartis in a research note on Wednesday, February 22nd. Zacks Investment Research lowered shares of Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, May 3rd. Finally, Cantor Fitzgerald began coverage on shares of Versartis in a research note on Thursday, May 4th. They issued an “overweight” rating and a $34.00 target price on the stock. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Versartis presently has a consensus rating of “Buy” and a consensus target price of $25.13.

A number of hedge funds have recently bought and sold shares of VSAR. Goldman Sachs Group Inc. boosted its stake in Versartis by 11.8% in the first quarter. Goldman Sachs Group Inc. now owns 100,784 shares of the biopharmaceutical company’s stock worth $2,152,000 after buying an additional 10,672 shares in the last quarter. Driehaus Capital Management LLC bought a new stake in Versartis during the first quarter worth approximately $4,117,000. HighTower Advisors LLC boosted its stake in Versartis by 126.5% in the first quarter. HighTower Advisors LLC now owns 23,325 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 13,025 shares in the last quarter. Credit Suisse AG boosted its stake in Versartis by 28.0% in the first quarter. Credit Suisse AG now owns 27,066 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 5,917 shares in the last quarter. Finally, EcoR1 Capital LLC bought a new stake in Versartis during the first quarter worth approximately $2,135,000. Hedge funds and other institutional investors own 70.15% of the company’s stock.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

12 Month Chart for NASDAQ:VSAR

Receive News & Ratings for Versartis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply